Ultragenyx Pharmaceutical Inc.

Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report?

RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals

QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target

Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results

Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More

Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet.

Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial

Ultragenyx's rare disease drug fails in late-stage trial; shares plunge

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

164,813 Shares in Ultragenyx Pharmaceutical Inc. $RARE Bought by Deutsche Bank AG

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

Ultragenyx Nabs FDA Nod for First Gene Therapy

Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript

Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx: Undervalued Ahead Of Two FDA Decisions